Simon M Laws

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4481263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Archives of Neurology, 2012, 69, 1318.	4.9	348
2	Expanding the association between theAPOEgene and the risk of Alzheimer's disease: possible roles forAPOEpromoter polymorphisms and alterations inAPOEtranscription. Journal of Neurochemistry, 2003, 84, 1215-1236.	2.1	197
3	Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Molecular Psychiatry, 2013, 18, 875-881.	4.1	185
4	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurology, The, 2016, 15, 1044-1053.	4.9	175
5	The role of beta amyloid in Alzheimer?s disease: still a cause of everything or the only one who got caught?. Pharmacological Research, 2004, 50, 397-409.	3.1	153
6	Plasma apolipoprotein E and Alzheimer disease risk. Neurology, 2011, 76, 1091-1098.	1.5	142
7	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 2011, 49, 2384-2390.	0.7	139
8	The Relationship between Sleep Quality and Brain Amyloid Burden. Sleep, 2016, 39, 1063-1068.	0.6	123
9	Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. Journal of Alzheimer's Disease, 2010, 20, 1233-1242.	1.2	122
10	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.4	114
11	Examination of the current top candidate genes for AD in a genome-wide association study. Molecular Psychiatry, 2010, 15, 756-766.	4.1	111
12	Risk prediction of late-onset Alzheimer's disease implies an oligogenic architecture. Nature Communications, 2020, 11, 4799.	5.8	110
13	BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	1.5	109
14	A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Molecular Psychiatry, 2014, 19, 519-526.	4.1	108
15	APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease. Molecular Psychiatry, 2015, 20, 1322-1328.	4.1	105
16	Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease. Molecular Psychiatry, 2014, 19, 69-75.	4.1	98
17	Aβ-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	2.5	96
18	Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies. Journal of Alzheimer's Disease, 2018, 62, 965-992.	1.2	96

Simon M Laws

#	Article	IF	CITATIONS
19	Olfactory discrimination predicts cognitive decline among community-dwelling older adults. Translational Psychiatry, 2012, 2, e118-e118.	2.4	93
20	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden. Translational Psychiatry, 2018, 8, 47.	2.4	92
21	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. Journal of Alzheimer's Disease, 2011, 27, 909-922.	1.2	83
22	The —491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. NeuroReport, 1999, 10, 879-882.	0.6	76
23	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer's disease. Nature Communications, 2020, 11, 5698.	5.8	76
24	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	1.1	75
25	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of Aging, 2015, 36, 1231-1238.	1.5	71
26	Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 488.	4.5	70
27	TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Human Mutation, 2005, 26, 29-35.	1.1	68
28	Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive and Personalised Medicine. International Journal of Molecular Sciences, 2018, 19, 390.	1.8	66
29	APOE-ε4 and APOE â^'491A polymorphisms in individuals with subjective memory loss. Molecular Psychiatry, 2002, 7, 768-775.	4.1	63
30	Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Molecular Psychiatry, 2007, 12, 510-517.	4.1	62
31	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific Reports, 2017, 7, 9766.	1.6	59
32	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	1.2	59
33	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.5	58
34	A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Human Molecular Genetics, 2015, 24, 5644-5654.	1.4	53
35	Variation at the APOE â^'491 promoter locus is associated with altered brain levels of apolipoprotein E. Molecular Psychiatry, 2002, 7, 886-890.	4.1	51
36	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease. Biological Psychiatry, 2003, 54, 136-141.	0.7	51

#	Article	IF	CITATIONS
37	Gonadotropins and Cognition in Older Women. Journal of Alzheimer's Disease, 2008, 13, 267-274.	1.2	51
38	Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Translational Psychiatry, 2018, 8, 238.	2.4	49
39	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	3.8	49
40	The <i>APOE</i> Îμ4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimer's Disease. ACS Chemical Neuroscience, 2017, 8, 1459-1464.	1.7	48
41	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated inÂPET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers andÂLifestyle (AIBL) study. Journal of Alzheimer's Disease, 2015, 48, 175-187.	1.2	47
42	Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. Journal of Alzheimer's Disease, 2018, 61, 1589-1598.	1.2	44
43	The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes. PLoS ONE, 2013, 8, e66235.	1.1	42
44	Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biological Psychiatry, 2003, 54, 616-622.	0.7	41
45	Olfactory Dysfunction is Associated with Subjective Memory Complaints in Community-Dwelling Elderly Individuals. Journal of Alzheimer's Disease, 2009, 17, 135-142.	1.2	39
46	A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease. Human Molecular Genetics, 2006, 15, 2446-2456.	1.4	37
47	Aβ-related memory decline in <i>APOE</i> Îμ4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.5	37
48	Chronic stress and <scp>A</scp> lzheimer's disease: the interplay between the hypothalamic–pituitary–adrenal axis, genetics and microglia. Biological Reviews, 2021, 96, 2209-2228.	4.7	37
49	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. Journal of Alzheimer's Disease, 2017, 58, 1293-1302.	1.2	35
50	Increased central adiposity is associated with pro-inflammatory immunoglobulin G N-glycans. Immunobiology, 2019, 224, 110-115.	0.8	34
51	Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology, 2021, 96, e662-e670.	1.5	34
52	Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 45-52.	1.1	32
53	Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	1.5	32
54	Apolipoprotein E4 is associated with reduced calcaneal quantitative ultrasound measurements and bone mineral density in elderly women. Bone, 2002, 31, 497-502.	1.4	31

#	Article	IF	CITATIONS
55	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports, 2018, 8, 2034.	1.6	31
56	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 18-26.	1.2	30
57	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nature Communications, 2022, 13, .	5.8	30
58	Assessing Reactive Astrogliosis with ¹⁸ F-SMBT-1 Across the Alzheimer Disease Spectrum. Journal of Nuclear Medicine, 2022, 63, 1560-1569.	2.8	29
59	Association of the Tau Haplotype H2 With Age at Onset and Functional Alterations of Glucose Utilization in Frontotemporal Dementia. American Journal of Psychiatry, 2007, 164, 1577-1584.	4.0	28
60	Association of alleles carried at TNFA -850 and BAT1-22 with Alzheimer's disease. Journal of Neuroinflammation, 2008, 5, 36.	3.1	28
61	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. Journal of Alzheimer's Disease, 2018, 63, 1299-1305.	1.2	28
62	Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Molecular Psychiatry, 2002, 7, 776-781.	4.1	27
63	Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease. Journal of Affective Disorders, 2018, 229, 269-274.	2.0	27
64	Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	1.2	27
65	Association of Cardiovascular Factors and Alzheimer's Disease Plasma Amyloid-β Protein in Subjective Memory Complainers. Journal of Alzheimer's Disease, 2009, 17, 305-318.	1.2	26
66	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.5	26
67	The Cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease. Human Mutation, 2006, 27, 532-537.	1.1	25
68	The Relationship Between Memory Complaints, Perceived Quality of Life and Mental Health in Apolipoprotein Eε4 Carriers and Non-Carriers. Journal of Alzheimer's Disease, 2009, 17, 69-79.	1.2	25
69	β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. American Journal of Geriatric Psychiatry, 2016, 24, 1191-1195.	0.6	25
70	SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 529-534.	1.8	24
71	Bone mineral density, adiposity, and cognitive functions. Frontiers in Aging Neuroscience, 2015, 7, 16.	1.7	23
72	Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults. Journal of Alzheimer's Disease, 2016, 52, 661-672.	1.2	23

#	Article	lF	CITATIONS
73	Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults. Archives of Clinical Neuropsychology, 2019, 34, 585-598.	0.3	23
74	Klotho allele status is not associated with Aβ and APOE ε4–related cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2019, 76, 162-165.	1.5	23
75	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 303-315.	1.2	23
76	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. PLoS ONE, 2015, 10, e0139082.	1.1	22
77	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimer's Research and Therapy, 2015, 7, 16.	3.0	22
78	Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures. Neurobiology of Aging, 2007, 28, 727-734.	1.5	21
79	BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF. International Psychogeriatrics, 2017, 29, 1825-1834.	0.6	21
80	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	1.2	21
81	Genetic resilience to Alzheimer's disease in <i>APOE</i> ε4 homozygotes: A systematic review. Alzheimer's and Dementia, 2019, 15, 1612-1623.	0.4	21
82	Rates of age―and amyloid βâ€associated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	1.2	21
83	Trajectories of depressive and anxiety symptoms in older adults: a 6â€year prospective cohort study. International Journal of Geriatric Psychiatry, 2018, 33, 405-413.	1.3	20
84	Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	1.2	19
85	Relationship Between Amyloid-Î ² Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	1.2	19
86	Association of Plasma Aß Peptides with Blood Pressure in the Elderly. PLoS ONE, 2011, 6, e18536.	1.1	19
87	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume. GeroScience, 2022, 44, 1807-1823.	2.1	19
88	No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia. Neurobiology of Aging, 2007, 28, 1789-1790.	1.5	18
89	Novel phage peptides attenuate beta amyloid-42 catalysed hydrogen peroxide production and associated neurotoxicity. Neurobiology of Aging, 2010, 31, 203-214.	1.5	17
90	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	1.7	16

Simon M Laws

#	Article	IF	CITATIONS
91	Does APOE genotype moderate the relationship between physical activity, brain health and dementia risk? A systematic review. Ageing Research Reviews, 2020, 64, 101173.	5.0	16
92	High-intensity exercise and cognitive function in cognitively normal older adults: a pilot randomised clinical trial. Alzheimer's Research and Therapy, 2021, 13, 33.	3.0	16
93	<i>APOE</i> Îμ2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.4	16
94	Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Scientific Reports, 2021, 11, 23788.	1.6	16
95	Lack of evidence to support the association of polymorphisms within the alpha- and beta-secretase genes (ADAM10/BACE1) with Alzheimer's disease. Neurobiology of Aging, 2011, 32, 541-543.	1.5	15
96	Study protocol of the Intense Physical Activity and Cognition study: The effect of highâ€intensity exercise training on cognitive function in older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 562-570.	1.8	15
97	Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition. Scientific Reports, 2019, 9, 17069.	1.6	15
98	The relationship between physical activity, apolipoprotein E ε4 carriage, and brain health. Alzheimer's Research and Therapy, 2020, 12, 48.	3.0	15
99	Neurological soft signs are associated with APOE genotype, age and cognitive performance. Journal of Alzheimer's Disease, 2005, 7, 325-330.	1.2	14
100	Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. Alzheimer's Research and Therapy, 2015, 7, 71.	3.0	14
101	Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia. Journal of Molecular Neuroscience, 2016, 60, 362-370.	1.1	14
102	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. Neurobiology of Aging, 2018, 70, 170-179.	1.5	14
103	<i>BDNF</i> VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease. Genes, Brain and Behavior, 2021, 20, e12724.	1.1	14
104	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer's disease. Personalized Medicine in Psychiatry, 2018, 7-8, 14-20.	0.1	13
105	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. Intelligence, 2018, 70, 22-29.	1.6	13
106	Subjective memory complaints predict baseline but not future cognitive function over three years: results from the Western Australia Memory Study. International Psychogeriatrics, 2019, 31, 513-525.	0.6	13
107	Resistance training enhances delayed memory in healthy middle-aged and older adults: A randomised controlled trial. Journal of Science and Medicine in Sport, 2019, 22, 1226-1231.	0.6	12
108	Association between the presenilin-1 mutation Glu318Gly and complaints of memory impairment. Neurobiology of Aging, 2002, 23, 55-58.	1.5	11

#	Article	IF	CITATIONS
109	Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiology of Aging, 2008, 29, 1276-1278.	1.5	11
110	Functional effects of genetic polymorphism in inflammatory genes in subjective memory complainers. Neurobiology of Aging, 2012, 33, 1054-1056.	1.5	11
111	Is Cholesterol and Amyloid-Î ² Stress Induced CD147 Expression a Protective Response? Evidence that Extracellular Cyclophilin A Mediated Neuroprotection is Reliant on CD147. Journal of Alzheimer's Disease, 2014, 39, 545-556.	1.2	11
112	The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity. Journal of Alzheimer's Disease, 2016, 50, 895-905.	1.2	10
113	Twelve weeks of resistance training does not influence peripheral levels of neurotrophic growth factors or homocysteine in healthy adults: a randomized-controlled trial. European Journal of Applied Physiology, 2019, 119, 2167-2176.	1.2	10
114	Influence of BDNF Val66Met on the relationship between cardiorespiratory fitness and memory in cognitively normal older adults. Behavioural Brain Research, 2019, 362, 103-108.	1.2	10
115	KLâ^—VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOEâ^—4 carriers. Neurobiology of Aging, 2021, 101, 123-129.	1.5	10
116	Sirtuin-1 mediates the obesity induced risk of common degenerative diseases: Alzheimer's disease, coronary artery disease and type 2 diabetes. Health, 2012, 04, 1448-1456.	0.1	10
117	No association of Vacuolar protein sorting 26 polymorphisms with Alzheimer's disease. Neurobiology of Aging, 2007, 28, 883-884.	1.5	9
118	APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2017, 57, 411-422.	1.2	9
119	The acceleration of aging and Alzheimer's disease through the biological mechanisms behind obesity and type II diabetes. Health, 2013, 05, 913-920.	0.1	9
120	Polymorphisms in CAMKK2 associate with susceptibility to sensory neuropathy in HIV patients treated without stavudine. Journal of NeuroVirology, 2019, 25, 814-824.	1.0	8
121	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. Journal of Alzheimer's Disease, 2020, 77, 733-744.	1.2	7
122	Age and APOE genotype affect the relationship between objectively measured physical activity and power in the alpha band, a marker of brain disease. Alzheimer's Research and Therapy, 2020, 12, 113.	3.0	7
123	The Peripheral Hearing and Central Auditory Processing Skills of Individuals With Subjective Memory Complaints. Frontiers in Neuroscience, 2020, 14, 888.	1.4	7
124	The role of CAMKK2 polymorphisms in HIV-associated sensory neuropathy in South Africans. Journal of the Neurological Sciences, 2020, 416, 116987.	0.3	7
125	Polygenic score modifies risk for Alzheimer's disease in <i>APOE</i> ε4 homozygotes at phenotypic extremes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12226.	1.2	7
126	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	1.2	7

#	Article	IF	CITATIONS
127	A Randomized Controlled Trial of High-Intensity Exercise and Executive Functioning in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2021, 29, 129-140.	0.6	6
128	Why Not Use the Immunoglobulin G N-Glycans as Predictor Variables in Disease Biomarker–Phenotype Association Studies? A Multivariate Analysis. OMICS A Journal of Integrative Biology, 2019, 23, 668-670.	1.0	5
129	COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults. IBRO Reports, 2019, 6, 147-152.	0.3	5
130	SPON1 Is Associated with Amyloid-β and APOE ε4-Related Cognitive Decline in Cognitively Normal Adults. Journal of Alzheimer's Disease Reports, 2021, 5, 111-120.	1.2	5
131	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.4	5
132	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer's disease, mild cognitive impairment, and healthy aging: A longitudinal study Psychological Assessment, 2018, 30, 1308-1316.	1.2	5
133	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF AÎ ² 42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	1.5	5
134	Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 7867.	1.8	5
135	No association of common VCP variants with sporadic frontotemporal dementia. Neurobiology of Aging, 2009, 30, 333-335.	1.5	4
136	Insights into the pathogenesis of normal-pressure hydrocephalus. Neurology, 2019, 92, 933-934.	1.5	4
137	Visual Memory Deficits in Middle-Aged APOE ɛ4 Homozygotes Detected Using Unsupervised Cognitive Assessments. Journal of Alzheimer's Disease, 2021, 79, 1563-1573.	1.2	4
138	Relevance of a Truncated PRESENILIN 2 Transcript to Alzheimer's Disease and Neurodegeneration. Journal of Alzheimer's Disease, 2021, 80, 1479-1489.	1.2	4
139	Brief Report: Demographic and Genetic Associations With Markers of Small and Large Fiber Sensory Neuropathy in HIV Patients Treated Without Stavudine. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 612-616.	0.9	4
140	ACTN3 (R577X) Genotype Is Associated With Australian Football League Players. Journal of Strength and Conditioning Research, 2022, 36, 573-576.	1.0	4
141	Comorbidity of Cerebrovascular andÂAlzheimer's Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	1.2	4
142	Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in Aβâ^² and Aβ+ Older Adults. Neurology, 2022, 98, e1704-e1715.	1.5	4
143	No association of lipase C polymorphisms with Alzheimer's disease. Neurobiology of Aging, 2010, 31, 2192-2193.	1.5	3
144	No association of Tachykinin receptor 2 (TACR2) polymorphisms with Alzheimer's disease. Neurobiology of Aging, 2011, 32, 544-545.	1.5	3

#	Article	IF	CITATIONS
145	TNF-Block Genotypes Influence Susceptibility to HIV-Associated Sensory Neuropathy in Indonesians and South Africans. International Journal of Molecular Sciences, 2020, 21, 380.	1.8	3
146	Personality factors and cerebral glucose metabolism in community-dwelling older adults. Brain Structure and Function, 2020, 225, 1511-1522.	1.2	3
147	Blood-Based Biomarkers in Alzheimer Disease: Where Are We Now and Where Have We to Go?—Reply. JAMA Neurology, 2013, 70, 133.	4.5	2
148	Association of Genetic Variances in ADRB1 and PPARGC1a with Two-Kilometre Running Time-Trial Performance in Australian Football League Players: A Preliminary Study. Sports, 2021, 9, 22.	0.7	2
149	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. Hormones and Behavior, 2021, 131, 104966.	1.0	2
150	Non-Modifiable Factors as Moderators of the Relationship Between Physical Activity and Brain Volume: A Cross-Sectional UK Biobank Study. Journal of Alzheimer's Disease, 2022, 88, 1091-1101.	1.2	2
151	Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease. BMC Genomics, 2022, 23, .	1.2	1
152	Association study between the D10S1423 microsatellite marker and Alzheimer's disease. Neurobiology of Aging, 2006, 27, 776.e1-776.e3.	1.5	0
153	P3-023: GENETIC VARIATION WITHIN GENES OF THE SPHINGOLIPID METABOLISM PATHWAY AND THEIR ASSOCIATION WITH ALZHEIMER'S DISEASE RISK AND RELATED PHENOTYPES. , 2014, 10, P635-P636.		0
154	[P4–134]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS. Alzheimer's and Dementia, 2017, 13, P1308.	0.4	0
155	P1â€142: PERIPHERAL INFLAMMATORY BURDEN BIOMARKERS MODULATE THE RISK FOR ALZHEIMER'S DISEASE THROUGH KEY ADâ€RELATED SNPS. Alzheimer's and Dementia. 2018. 14. P330.	0.4	0